We think this will help. .. A molecular probe that might one day light up tumors while surgery is in progress Researchers in the Stanford University College of Medicine are suffering from a molecular probe that sets aglow tumor cells within living pets. Their goal is by using the probe to improve the procedure and diagnosis of cancer and other diseases. The probe’s main ingredient can be a molecule that labels energetic proteases – protein-destroying enzymes – that operate amok in cancerous cells. The molecule is generally invisible to the naked eye but it carries a fluorescent tag that lighting up when it binds to the protease.Jacobson, M.D., Stuart C. Gordon, M.D., Kris V. Kowdley, M.D., Eric M. Yoshida, M.D., Maribel Rodriguez-Torres, M.D., Tag S. Sulkowski, M.D., Mitchell L. Shiffman, M.D., Eric Lawitz, M.D., Gregory Everson, M.D., Michael Bennett, M.D., Eugene Schiff, M.D., M. Tarek Al-Assi, M.D., G. Mani Subramanian, M.D., Ph.D., Di An, Ph.D., Ming Lin, Ph.D., John McNally, Ph.D., Diana Brainard, M.D., William T. Symonds, Pharm.D., John G. McHutchison, M.D., Keyur Patel, M.D., Jordan Feld, M.D., M.P.H., Stephen Pianko, M.D., Ph.D., and David R. Nelson, M.D.1-4 However, a considerable proportion of individuals with HCV disease remain untreated due to total or relative contraindications to interferon therapy, such as hepatic decompensation, autoimmune disease, and psychiatric illness.5 In addition, interferon causes a variety of constitutional symptoms or hematologic abnormalities that may require discontinuation of therapy in a considerable number of patients.6 Some sufferers decide against interferon therapy for a variety of reasons, including aversion to injections and anxiety about the adverse events associated with treatment.